3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
6
Completed
2
Withdrawn
1
Terminated
1
Recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Carcinoma, Squamous Cell
1
Anemia, Refractory, with Excess of Blasts
1
Allogeneic Stem Cell Transplantation
1
Interventions
Peripheral Blood Stem Cell Transplantation
5
fludarabine phosphate
4
Cyclosporine
3
Cyclophosphamide
3
Whole-Body Irradiation
2
Tacrolimus
2
Pentetic Acid
2
Mycophenolic Acid
2
Methotrexate
2
Filgrastim
2
Cytarabine
2
Cyclosporins
2
Busulfan
2
Azacitidine
2
venetoclax
1
tamibarotene
1
olutasidenib
1
merphos
1
ethanolamine oleate
1
decitabine and cedazuridine drug combination
1
bisantrene
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Therapeutics
1
Sulfamethoxazole
1
Sodium Chloride
1
Sitagliptin Phosphate
1
Saline Solution, Hypertonic
1
Saline Solution
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Leukemia, Myelomonocytic, Chronic
×
decitabine and cedazuridine drug combination
×
Clear all
NCT05456269
2023-10-03
BISECT
Racura Oncology Ltd
Phase 1
Withdrawn